您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报 (医学版) ›› 2018, Vol. 56 ›› Issue (5): 35-40.doi: 10.6040/j.issn.1671-7554.0.2018.233

• • 上一篇    下一篇

复发和未控卵巢恶性生殖细胞肿瘤保留生育功能的治疗

王瑾晖1,杨佳欣1,袁振1,曹冬焱1,沈铿1,黄惠芳1,吴鸣1,潘凌亚1,郭丽娜2   

  1. 中国医学科学院北京协和医学院 北京协和医院 1. 妇产科;2. 病理科, 北京 100730
  • 收稿日期:2018-02-22 发布日期:2022-09-27
  • 通讯作者: 杨佳欣. E-mail:YangJiaXin@pumch.cn
  • 基金资助:
    国家科技部十一五国家科技支撑计划(2008BAI57B02)

Preserve fertility in recurrent and uncontrolled malignant ovarian germ cell tumors

WANG Jinhui1, YANG Jiaxin1, YUAN Zhen1, CAO Dongyan1, SHEN Keng1, HUANG Huifang1, WU Ming1, PAN Lingya1, GUO Lina2   

  1. 1. Department of Obstetrics and Gynaecology;
    2. Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Science &
    Peking Union Medical College, Beijing 100730, China
  • Received:2018-02-22 Published:2022-09-27

PDF (PC)

85

摘要： 目的 探讨复发和未控卵巢恶性生殖细胞肿瘤(MOGCT)的临床特征、挽救性治疗、预后,以及患者接受再次保留生育功能治疗的可行性。 方法 回顾性分析2000年1月1日至2017年3月31日期间收治的41例复发和未控MOGCT患者的临床资料。 结果 初次手术中保留生育功能治疗后MOGCT 41例中,复发患者18例(43.9%),未控患者23例(56.1%),6~37岁,根据2014年国际妇产科联盟(FIGO)手术病理或临床评估分期:Ⅰ期25例,Ⅱ期1例,Ⅲ期14例,Ⅳ期1例。未成熟畸胎瘤18例,卵黄囊瘤14例,无性细胞瘤1例,混合生殖细胞肿瘤8例。31例进行了保留生育功能的再次肿瘤细胞减灭术,8例进行了不保留生育功能的肿瘤细胞减灭术。失访2例,在复发后中位随诊30.3个月的随诊期内,再次复发13例(33.3%),死亡10例(25.6%)。复发后5年生存率和复发后无进展生存率分别为71.5%和68.7%。分期和复发后再次肿瘤细胞减灭术的手术满意程度是影响预后的独立因素(P=0.03; P=0.01)。 结论 MOGCT初次规范治疗是减少复发和未控的关键。对于复发或未控MOGCT,满意的肿瘤细胞减灭术加标准的化疗对预后起着至关重要的作用。对年轻未生育患者可以考虑再次保留生育功能的挽救性治疗。

关键词: 卵巢恶性生殖细胞肿瘤, 复发, 未控, 化疗, 挽救性手术

Abstract: Objective To explore the clinical characteristics, salvage therapy and prognosis of recurrent and uncontrolled malignant ovarian germ cell tumor(MOGCT)and to evaluate the possibility of secondary fertility-sparing surgery. Methods The clinical data of 41 recurrent and uncontrolled MOGCT cases treated during Jan. 1st, 2000 and Mar. 31st, 2017 were retrospectively analyzed. Results There were 18 recurrent and 23 uncontrolled cases. The patients age ranged from 6 to 37 years. FIGO stage: stage I in 25 cases, stage II in 1 case, stage III in 14 cases, and stage IV in 1 case. There were 18 cases of immature teratoma, 14 cases of yolk sac tumor, 1 case of dysgerminoma and 8 cases of mixed germ cell tumor. Secondary fertility-sparing cytoreductive surgery was performed in 31 cases, and secondary cytoreductive surgery without fertility-sparing was performed in 8 cases. During the median follow-up of 30.3 months after recurrence, 2 cases were loss to follow-up, 13 cases(33.3%)had a second relapse, and 10 patients(25.6%)died. The 5-year survival rate after recurrence was 68.7%, and the 5-year progress-free survival rate after recurrence 山 东 大 学 学 报 (医 学 版)56卷5期 -王瑾晖,等.复发和未控卵巢恶性生殖细胞肿瘤保留生育功能的治疗 \=-was 71.5%. FIGO stage and patients satisfaction with cytoreductive surgery were the independent prognostic factors(P<0.05). Conclusion The standardized primary therapy should be emphasized in the treatment of MOGCT. For recurrent and uncontrolled MOGCT, optimal cytoreductive surgery and adjuvant standardized chemotherapy have significant impacts on the prognosis of patients. For young nulliparous patients, secondary fertility-sparing salvage therapy can be taken into consideration.

Key words: Malignant ovarian germ cell tumor, Recurrence, Uncontrolled tumor, Chemoherapy, Salvage surgery

中图分类号: 

  • R737.31
[1] Brown J, Friedlander M, Backes FJ, et al. Gynecologic cancer intergroup(GCIG)consensus review for ovarian germ cell tumors[J]. Int J Gynecol Cancer, 2014, 24(9 Suppl 3): S48-54.
[2] Mangili G, Sigismondi C, Gadducci A, et al. Outcome and risk factors for recurrence in malignant ovarian germ cell tumors: a MITO-9 retrospective study[J]. Int J Gynecol Cancer, 2011, 21(8): 1414-1421.
[3] Wang HB, Yang JX, Shen K, et al. Treatment of recurrent and persistent malignant ovarian germ cell tumors[J]. J Reprod Med, 2009, 18(S2): 64-68.
[4] Segelov E, Campbell J, Ng M, et al. Cisplatin-based chemotherapy for ovarian germ cell malignancies: the Australian experience[J]. J Clin Oncol, 1994, 12(2): 378-384.
[5] Dimopoulos MA, Papadopoulou M, Andreopoulou E, et al. Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: a Hellenic Cooperative Oncology Group study[J]. Gynecol Oncol,1998, 70(1): 70-74.
[6] Dimopoulos MA, Papadimitriou C, Hamilos G, et al. Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study[J]. Gynecol Oncol, 2004, 95(3): 695-700.
[7] Murugaesu N, Schmid P, Dancey G, et al. Malignant ovarian germ cell tumors: identification of novel prognostic markers and longterm outcome after multimodality treatment[J]. J Clin Oncol, 2006, 24(30): 4862-4866.
[8] 中华医学会妇科肿瘤学分会. 妇科恶性肿瘤保留生育功能临床诊治指南[J]. 中华妇产科杂志, 2014, 49(4): 243-248.
[9] Park JY, Kim DY, Suh DS, et al. Outcomes of pediatric and adolescent girls with malignant ovarian germ cell tumors[J]. Gynecol Oncol, 2015, 137(3): 418-422.
[10] Morris M, Gershenson DM, Burke TW, et al. Treatment of fallopian tube carcinoma with cisplatin, doxorubicin, and cyclophosphamide[J]. Obstet Gynecol, 1990, 76(6): 1020-1024.
[11] Williams S, Blessing JA, Liao SY, et al. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group[J]. J Clin Oncol, 1994, 12(4): 701-706.
[12] Li J, Wu X. Current strategy for the treatment of ovarian germ cell tumors role of extensive surgery[J]. Curr Treat Options in Oncol, 2016, 17(8): 44. doi: 10.1007/s11864-016-0416-2.
[13] Ertas IE, Taskin S, Goklu R, et al. Long-term oncological and reproductive outcomes of fertility-sparing cytoreductive surgery in females aged 25 years and younger with malignant ovarian germ cell tumors[J]. J Obstet Gynaecol Res, 2014, 40(3): 797-805.
[14] Siriwan T, Jitti H, Sumonmal M, et al. Malignant ovarian germ cell tumors: clinico-pathological presentation and survival outcomes[J]. Acta Obstet Gynecol Scand, 2010, 89(2): 182-189.
[15] Reddihalli PV, Subbian A, Umadevi K, et al. Immature teratoma of ovary—outcome following primary and secondary surgery: study of a single institution cohort[J]. Eur J Obstet Gynecol Reprod Biol, 2015, 192: 17-21. doi: 10.1016/j.ejogrb.2015.06.017. Epub 2015 Jun 25.
[16] Munkarah A, Gershenson DM, Levenback C, et al. Salvage surgery for chemorefractory ovarian germ cell tumors[J]. Gynecol Oncol, 1994, 55(2): 217-223.
[17] Li J, Yang W, Wu X. Prognostic factors and role of salvage surgery in chemorefractory ovarian germ cell malignancies: a study in Chinese patients[J]. Gynecol Oncol, 2007, 105(3): 769-775.
[18] Yang ZJ, Liu ZC, Wei RJ, et al. An analysis of prognostic factors in patients with ovarian malignant germ cell tumors who are treated with fertility-preserving surgery[J]. Gynecol Obstet Invest, 2016, 81(1): 1-9.
[19] Alcázar JL, Guerriero S, Pascual Má, et al. Clinical and sonographic features of uncommon primary ovarian malignancies[J]. J Clin Ultrasound, 2012, 40(6): 323-329.
[20] Liu Q,Ding X, Yang JX, et al. Multicenter randomized controlled clinical study for the operative treatment of malignant ovarian germ cell tumors[J]. Chin J Obstet Gynecol, 2013, 48(3): 188-192.
[21] 沈铿. 妇科恶性肿瘤保留生育功能治疗应注意的几个问题[J]. 中华妇产科杂志, 2006, 41(4): 219-221.
[22] 杨佳欣, 向阳. 复发性耐药性卵巢恶性生殖细胞肿瘤的治疗[J]. 中国实用妇科与产科杂志, 2015, 3(31): 201-211. YANG Jiaxin, XIANG Yang. Treatment of recurrent and uncontrolled malignant ovarian germ cell tumors[J]. Chin J Prac Gynecol Obstetr, 2015, 3(31): 201-211.
[23] Rashdan S, Einhorn LH. Salvage therapy for patients with germ cell tumor[J]. J Oncol Pract, 2016, 12(5): 437-443.
[24] Simone CG, Markham MJ, Dizon DS. Chemotherapy in ovarian germ cell tumors: a systematic review[J]. Gynecol Oncol, 2016, 141(3): 602-607.
[25] Reddy Ammakkanavar N, Matei D, Abonour R, et al. High-dose chemotherapy for recurrent ovarian germ cell tumors[J]. J Clin Oncol, 2015, 33(2): 226-227.
[26] De Giorgi U, Richard S, Badoglio M, et al. Salvage high-dose chemotherapy in female patients with relapsed/refractory germ-cell tumors: a retrospective analysis of the European Group for Blood and Marrow Transplantation(EBMT)[J]. Ann Oncol, 2017, 28(8):1910-1916.
[1] 张莹 王宏伟 王慧 陈福琴. Graves病复发患者外周血中转化生长因子β1水平的变化[J]. 山东大学学报(医学版), 2209, 47(6): 80-.
[2] 万文静,高姗姗. 低分子肝素在生殖领域的应用[J]. 山东大学学报 (医学版), 2025, 63(6): 117-124.
[3] 杨卫芳,徐宏,刘元涛,赵蕙琛. 促甲状腺激素受体抗体在Graves病复发中的作用机制及其临床意义[J]. 山东大学学报 (医学版), 2025, 63(4): 116-121.
[4] 李永,崔书君,杨飞,张凡,殷晓霞. 基于增强MRI的亚区域影像组学模型可预测乳腺癌患者新辅助化疗后的病理完全反应[J]. 山东大学学报 (医学版), 2025, 63(1): 81-89.
[5] 张荣雨,赵文,李洪欣,杨闯,王健,韩春燕,李际盛. 奥西替尼联合化疗一线治疗EGFR-RAD51融合突变转移性肺腺癌1例[J]. 山东大学学报 (医学版), 2024, 62(5): 116-120.
[6] 石军,牛子捷,王军,马丽晶,奚春花,肖洋. 幼年型复发性呼吸道乳头状瘤病肺部播散的临床特点及麻醉要点[J]. 山东大学学报 (医学版), 2024, 62(12): 82-89.
[7] 唐小雨,王云彦,史有奎,王敏. 肉芽肿性多血管炎继发肥厚性硬脑膜炎1例[J]. 山东大学学报 (医学版), 2023, 61(5): 122-124.
[8] 李晴,张安娜,杜艳圣,刁久洲,崔若瑾,付鹏蕊,岳欣毅,周庆博. 47例单个脊髓炎性脱髓鞘病灶转化的影响因素[J]. 山东大学学报 (医学版), 2023, 61(5): 37-43.
[9] 韩明勇,于晓黎,曾放平,谢兵,芦兰,瞿家权,江璧锋,唐斯晗,谭洁,梁瑾,钟龙辉,王柳,赵宣植. CT引导经皮肺穿刺肿瘤内化疗技术流程[J]. 山东大学学报 (医学版), 2023, 61(11): 11-19.
[10] 阮祥燕,程姣姣,杜娟,谷牧青. 卵巢组织冷冻保存[J]. 山东大学学报 (医学版), 2022, 60(9): 24-30.
[11] 秦静,杨飞,陈谦,夏涵岱,刘延国,王秀问. 晚期驱动基因阴性、PD-L1表达阴性非鳞非小细胞肺癌一线治疗方案的网状Meta分析[J]. 山东大学学报 (医学版), 2022, 60(7): 74-82.
[12] 左立平,蒋丰洋,周斌彬,范金蕾,梁永锋,邓展昊,于德新. 术前MRI在预测169例肝细胞肝癌微血管侵犯及早期复发的价值[J]. 山东大学学报 (医学版), 2022, 60(3): 89-95.
[13] 马瑞杰,朱良明,左太阳,李春海,张楠,孙志钢. 微波消融治疗非小细胞肺癌根治术后肺寡转移瘤的预后分析[J]. 山东大学学报 (医学版), 2022, 60(12): 63-68.
[14] 丁子琛,王浩桦,周立雯,丛慧文,李承圣,包绮晗,杨毅,王廉源,王素珍,石福艳. 基于贝叶斯累加回归树模型的非小细胞肺癌患者个性化疗效研究[J]. 山东大学学报 (医学版), 2022, 60(10): 92-98.
[15] 初竹秀,赵文静,李小燕,孔晓丽,马婷婷,江立玉,杨其峰. 218例女性乳腺癌患者行新辅助化疗及伴随分子标志物改变的临床价值[J]. 山东大学学报 (医学版), 2021, 59(9): 130-139.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发